Boehringer Exercises Option in Oxford Bio Alliance

Boehringer Ingelheim has exercised an option for exclusive rights to an oncology target under an ongoing discovery collaboration with Oxford BioTherapeutics. The target was discovered using Oxford’s OGAP system, which incorporates one of the largest proteomic databases, integrating clinical, experimental and expression data.
 
This is the first option exercised under the oncology target discovery and validation collaboration established in 2013. Boehringer Ingelheim is responsible for the future development and commercialization of antibody products and Oxford will receive development and regulatory milestones, and royalties on any product sales.
 
“We are delighted to have reached this important milestone in the collaboration with Boehringer Ingelheim, which validates both our ongoing collaboration with a world-leading oncology company and our unique OGAP target discovery system,” said Dr. Christian Rohlff, chief executive officer of Oxford BioTherapeutics. “Antibody therapeutics are a focus area for oncology R&D, and the selection of their targets is important for their success.”